“…Compounds with the five-membered isoxazole, isothiazole and 1,3,4-thiadiazole heterocycles possess high potential for biological activity and are privileged scaffolds for the development of pharmaceutical agents (Das & Chanda, 2021;Kletskov et al, 2020;Khalilullah et al, 2014;Yadigarov et al, 2009;Safavora et al, 2019;Zubkov et al, 2014). In particular, isoxazoles are able to enhance the action of 'first-line' antitumor substances, which makes it possible to reduce their therapeutic doses and thus reduce toxic side effects (Khalilov et al, 2021;Kulchitsky et al, 2012;Naghiyev et al, 2020).…”